October 26, 2009
Certain Antidepressants May Inhibit Herpesvirus
Infection and Reactivation
The viruses that cause cold sores, chickenpox, and shingles require a host cell protein complex to initiate infection, but certain antidepressants appear to disrupt the activity of that complex and potentially prevent infection, according to scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
In a study now online in Nature Medicine, a research group led by Thomas M. Kristie, Ph.D., chief of the Molecular Genetics Section in the NIAID Laboratory of Viral Diseases, found that the host enzyme LSD1 interacts with a key host protein (HCF-1) that the herpesviruses require to infect host cells. In these cell and tissue studies, which involved herpes simplex virus (HSV) and varicella-zoster virus (VZV), HCF-1 was required to recruit LSD1 to the viral genome and initiate infection. HSV infection can cause cold sores and genital lesions, and VZV infection causes chickenpox and shingles.
When Dr. Kristie’s group reduced levels of either HCF-1 or LSD1, they noticed a corresponding decrease in the ability of HSV and VZV to express the viral genes necessary to continue infection. These results established the relationship between LSD1 and HCF-1 and the importance of each protein in initiating both HSV and VZV infections.
The scientists also knew from previous studies that LSD1 is similar to a family of enzymes whose activity is inhibited by monoamine oxidase inhibitors (MAOIs)—drugs used to treat clinical depression, anxiety and other disorders.
Therefore, the researchers tested the ability of the MAOI drugs pargyline and tranylcypromine (TCP) to inhibit HSV and VZV infection and observed significantly decreased levels of virus. The observation identified LSD1 as an essential control component and target for preventing herpesvirus infection.
After the initial infection, both HSV and VZV enter a latent state in nerve cells of the infected host. Periodically these viruses can reactivate to produce infection and disease. The researchers demonstrated that, in addition to preventing infection, the MAOI drug TCP also prevented HSV reactivation. Importantly, says Dr. Kristie, the study contributes to the understanding of the mechanisms used by these viruses to infect host cells and of their cycles of latency-reactivation.
“As LSD1 is a well-defined target of MAOIs and these pharmaceuticals are widely used therapeutically, these observations identify a novel therapeutic target for herpesvirus infections and enhances the importance of ongoing efforts to develop additional LSD1 inhibitors,” the study states.
The researchers are continuing to analyze the unique HCF-1 protein complex to identify other components that are important for initiating herpesvirus infections and reactivating these viruses from latency.
Media inquiries can be directed to the NIAID Office of Communications at 301-402-1663, email@example.com.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated October 26, 2009